Drug Trial Radar · NCT04085523
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Jun 24, 2020
Primary completion
Sep 27, 2022
Study completion Oct 1, 2024
Sponsor
- Lead sponsor
- Ascendis Pharma A/SIndustry
- Sponsor type
- Industry
- First posted
- Sep 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10 years old, inclusive, with Achondroplasia.
Conditions
- Achondroplasia
Interventions
TransCon CNPDrug
TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
Placebo for TransCon CNPDrug
Weekly subcutaneously injection of placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Height Velocity (cm/Year) After 52 Weeks of Double-blind TreatmentTime frame: 52 weeks
Locations
15 sites in 8 countries. Site status is shown where the registry gives one.
Ascendis Pharma Investigational Site
Little Rock, Arkansas
Ascendis Pharma Investigational Site
Aurora, Colorado
Ascendis Pharma Investigational Site
Saint Paul, Minnesota
Ascendis Pharma Investigational Site
Columbia, Missouri
Ascendis Pharma Investigational Site
Buffalo, New York
Ascendis Pharma Investigational Site
Houston, Texas
Ascendis Pharma Investigational Site
Seattle, Washington
Ascendis Pharma Investigational Site
Madison, Wisconsin
Ascendis Pharma Investigational Site
Parkville, Victoria, Australia
Ascendis Pharma Investigational Site
Linz, Austria
Ascendis Pharma Investigational Site
Copenhagen, Denmark
Ascendis Pharma Investigational Site
Berlin, Germany
Ascendis Pharma Investigational Site
Dublin, Ireland
Ascendis Pharma Investigational Site
Auckland, New Zealand
Ascendis Pharma Investigational Site
Coimbra, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.